{
  "ticker": "LLY",
  "target_date": "2025-08-19",
  "actual_date": "2025-08-19",
  "collected_at": "2025-12-08T12:09:46.186121",
  "price": {
    "open": 705.57,
    "high": 713.22,
    "low": 697.53,
    "close": 702.1787719726562,
    "volume": 5941000,
    "change_1d_pct": 0.74,
    "change_7d_pct": 12.64,
    "change_30d_pct": -9.37
  },
  "technicals": {
    "rsi_14": 40.04,
    "sma_20": 723.6,
    "sma_50": 758.68,
    "macd": -24.381,
    "macd_signal": -24.367,
    "macd_histogram": -0.013,
    "bb_upper": 848.42,
    "bb_lower": 598.78,
    "price_vs_sma20_pct": -2.96,
    "price_vs_sma50_pct": -7.45,
    "volume_ratio": 0.87
  },
  "fundamentals": {
    "market_cap": 892341977088,
    "pe_ratio": 48.7707,
    "forward_pe": 43.928066,
    "price_to_book": 37.477787,
    "price_to_sales": 15.017587,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.48,
    "pct_from_52w_low": 59.58
  },
  "macro": {
    "spy": {
      "price": 638.04,
      "change_1d_pct": -0.54,
      "change_7d_pct": 0.61
    },
    "vix": {
      "level": 15.57,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.3
    },
    "dollar_index": {
      "level": 98.27
    },
    "gold": {
      "price": 3313.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Hartford Core Equity Fund Q2 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1755646500,
      "summary": "Hartford Core Equity (I share) underperformed the S&P 500 Index during the quarter. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=dd26b9300223d39082b52e239e1f9e3dd31d3237afb0433c8072528e1ef7d45a"
    },
    {
      "headline": "Viking Therapeutics stock plunges: Weight-loss pill trial disappoints",
      "source": "Yahoo",
      "datetime": 1755633369,
      "summary": "Viking Therapeutics (VKTX) shares plunge after revealing a high dropout rate in the phase 2 trial for its weight-loss pill.\u00a0 Yahoo Finance Senior Health Reporter Anjalee Khemlani outlines the latest and what to watch. To watch more expert insights and analysis on the latest market action, check out ",
      "url": "https://finnhub.io/api/news?id=a431b73639792fa86f26aa79937aa5635a435ce5118bd2dcb005e0ca1157121c"
    },
    {
      "headline": "Viking\u2019s stock plummets on obesity pill trial results",
      "source": "Yahoo",
      "datetime": 1755626587,
      "summary": "VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.",
      "url": "https://finnhub.io/api/news?id=69984b00a914d9bdd19b8702e99c278f778c5e717123ece1e9dce6a342326605"
    },
    {
      "headline": "Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell",
      "source": "SeekingAlpha",
      "datetime": 1755626139,
      "summary": "Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this raises doubts about VKTX and its future.",
      "url": "https://finnhub.io/api/news?id=1d3b1820dae40ec15e092f210905d072fd5ba942232f2d92e8569d698d10c552"
    },
    {
      "headline": "Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone",
      "source": "Yahoo",
      "datetime": 1755623392,
      "summary": "Shares of Viking Therapeutics (VKTX) tumbled intraday Tuesday after the company released trial data",
      "url": "https://finnhub.io/api/news?id=309106de6e2e77fe1966fd0d333a42f0a11944d01e74e427e1145068f98ca2d9"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634943.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000230/xslF345X05/wk-form4_1755634943.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634883.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000228/xslF345X05/wk-form4_1755634883.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634822.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000226/xslF345X05/wk-form4_1755634822.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634774.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000224/xslF345X05/wk-form4_1755634774.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}